CompletedPHASE2, PHASE3NCT05256017
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
Studying African trypanosomiasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Drugs for Neglected Diseases
- Principal Investigator
- Victor Kande Betu Kumeso, Dr.Ministry of Public Health, Hygiene and Prevention, Kinshasa
- Intervention
- Acoziborole(drug)
- Enrollment
- 1208 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2021 – 2023
Study locations (7)
- General Referral Hospital of Bagata, Bagata, Bandundu, Democratic Republic of the Congo
- Hospital of Dipumba, Mbuji-Mayi, East Kasai, Democratic Republic of the Congo
- General Referral Hospital of Idiofa, Idiofa, Kwilu, Democratic Republic of the Congo
- General Referral Hospital of Masi-Manimba, Masi-Manimba, Kwilu, Democratic Republic of the Congo
- General Referral Hospital of Kwamouth, Kwamouth, Mai Ndombe, Democratic Republic of the Congo
- General Referral Hospital of Bandundu, Bandundu Province, Democratic Republic of the Congo
- General Referral Hospital of Dubreka, Dubréka, Guinea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05256017 on ClinicalTrials.govOther trials for African trypanosomiasis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07106385The Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) on Improving Sleep Quality in Adults Without Serious Mental IllnessThe University of Hong Kong
- ACTIVE NOT RECRUITINGNCT04565769Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint InhibitorsAarhus University Hospital
- RECRUITINGNCT01778504Studying Childhood-onset Behavioral, Psychiatric, and Developmental DisordersNational Institute of Mental Health (NIMH)